Skip to main content

CART

Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

  • RegistryNCT07319676
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionB-cell Lymphoma Refractory
  • SponsorNational University Hospital, Singapore
How CART worksNCT073196761 min

What the film says

Read the transcript

CAR T cells against CD19 have changed the outlook for relapsed B-cell lymphoma. But after rounds of chemotherapy, a patient's T cells are worn down, and the engineered cells may fail to expand.

The idea: give the cells a receptor for a growth signal the body already makes.

At National University Hospital in Singapore, a patient's T cells receive the CD19 receptor together with a receptor for erythropoietin, the hormone that drives red blood cell production, so natural or supplemental erythropoietin can feed the T cells too. If the biopsy shows CD22 as well, a second CAR T product is added, making escape harder.

A safety study leading into phase two, ages ten to eighty. Michelle Poon leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07319676

    Suboptimal T-cell expansion/persistence after prior chemotherapy; Epo-R co-expression lets endogenous or exogenous Epo support CAR T survival and expansion; Target choice by flow cytometry of biopsied lymphoma; CD22 CAR T pooled product; Phase 1 lead-in for RP2D then phase 2; ages 10–80 (+1 more lines)

The drug

What is being tested.

CART cells originate with the isolation of the patient's T cells via apheresis. These cells are then activated and modified to express a transgene that encodes a tumor-specific CAR. These cells are then expanded to achieve a clinically significant cell dose which will then be infused back into the patient.

2.1 Hypothesis 1. The infusion of CD19 with or without CD 22 targeted CAR T-cells in patients with high risk or R/R BCL will improve the overall response rates and survival outcomes. The choice of antigen target is determined by detailed flow cytometric profiling of biopsied lymphoma cells if possible. 2.

The co-expression of Epo-R in our CD19 CAR T-cells will allow endogenous or exogenous Epo levels to support survival and expansion of infused T cells, thus overcoming the issue of suboptimal T-cell expansion and persistence due to prior chemotherapies in patients with high risk or R/R DLBCL.

The study

How the trial runs.

This is a single center, open label, phase 1 lead in to determine Recommended Phase 2 Dose (RP2D), followed by a phase 2 trial to evaluate the safety and efficacy of Epo-R-CD19 CAR T with or without CD22 CAR T-cells infused into patients with B cell lymphoma.

The study will have the following parts: * Screening * Pre-infusion (cell product preparation and bridging) and infusion (lymphodepletion) * Primary efficacy endpoints * Long term follow up Patients who have high risk B cell lymphoma or relapsed/refractory B cell lymphoma who fufil the trial inclusion and exclusion criteria will undergo leukapheresis following trial enrollment.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Age 10 to 80 years at screening
  • PET-CT measurable disease by Lugano classification (Deauville score of ≥4) and
  • Tissue biopsy of any tumour site and flow cytometry study of CD19 and CD22 expression.
  • Relapsed B-cell lymphoma after one line of systemic therapy or autologous bone marrow transplant. This includes DLBCL, PMBCL, HGBCL, DLBCL arising from indolent lymphoma, Burkitt's lymphoma/leukemia, Mantle cell lymphoma.
  • High risk B-cell lymphoma (BCL). High risk BCL is defined by any of the criteria below:
  • High-risk genetics - double/triple hit or p53mut or deletion.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.